We recognize that, as our data identify MEKK1 as a regulator of multiple chemokines, selective MEKK1 inhibition may have functional consequences that far exceed the impact of CCR5 inhibition alone (e.g. immune function) that will influence the utility of MEKK1 inhibitors as cancer therapeutic agents. This evidence concerns the gene MAP3K1 and cancer.